

BARRY GREENE
CHIEF EXECUTIVE OFFICER
MEMBER OF BOARD OF DIRECTORS

Barry E. Greene joined Sage as CEO in December of 2020, bringing more than 30 years of biopharmaceutical industry experience to this position. He previously joined the Sage Board of Directors in October of 2020. Prior to Sage, he served as president of Alnylam Pharmaceuticals, Inc. since 2007, and he previously held the position of chief operating officer when he first joined the company in 2003. Prior to his 17 year tenure at Alnylam, Mr. Greene was the general manager of Oncology at Millennium Pharmaceuticals, Inc. where he led the Company's global strategy and execution for its oncology business, including strategic business direction and execution, culminating in the successful U.S. Food and Drug Administration approval and launch of VELCADE® (bortezomib) in mid-2003. Prior to joining Millennium in 2001, Mr. Greene served as executive vice president and chief business officer for Mediconsult.com, a healthcare consulting company. Earlier in Mr. Greene's career, he held multiple leadership positions at AstraZeneca (formerly AstraMerck), and was a partner of Andersen Consulting, where he was responsible for the pharmaceutical/biotechnology marketing and sales practice.

He received his B.S. in Industrial Engineering from the University of Pittsburgh and served as a Senior Scholar at Duke University's Fuqua School of Business.